Brammer Bio, a contract development and manufacturing organization (CDMO) for companies developing gene-modified cell therapies and in vivo gene therapies, has made leadership appointments to support the growth of the organization.
 
Steve Falcone joins Brammer as chief quality officer, reporting directly to Brammer’s president and chief executive officer, Mark Bamforth. Steve brings 22 years of industry experience, most recently from Sanofi where he was overseeing quality for three commercial biologics manufacturing sites. Prior to Sanofi, he was with Amgen where he had key roles, which included head of external affairs in the international quality organization and general manager of two of Amgen’s facilities with responsibility for viral-based cancer therapy manufacturing. 
 
Chris Murphy has been appointed chief operations officer. Chris joined Brammer as chief manufacturing officer in June 2017 and played a key role in leading the company to expand its Alachua, FL site, complete the Cambridge, MA commercial build-out and start-up in 2018, and develop and execute plans for viral vector manufacturing in Lexington, MA.
 
In addition, Steve Favaloro has been appointed chief financial officer. Steve has been a part of the senior Brammer leadership team since May 2016 in various roles, most recently vice president of finance and accounting. He became an officer of Brammer Bio in January 2018.
 
“We are thrilled to welcome Steve Falcone to Brammer Bio,” said Mr. Bamforth. “His quality knowledge and experience in leading commercial quality organizations is invaluable. The internal appointments of Chris Murphy and Steve Favaloro will better position us for future success to enable our clients in Helping to Cure.”